Polymorphism is the ability of a compound to exist in multiple solid forms. The Polymorph is a critical aspect of pharmaceutical development, influencing everything from drug solubility, stability, bioavailability, manufacturability, regulatory success, and intellectual property strategy.
Knowing Polymorphism isn’t just a best practice — it’s a regulatory expectation and a strategic advantage. Whether you’re seeking market exclusivity or rapid generic launch, polymorph intelligence is the foundation of confident, competitive product development.
Crystal Atlas is a proprietary, ready-to-use intelligence platform featuring all reported polymorphic forms for pharmaceutical products approved globally since 2020 (small molecules - first time approvals).
It includes a comprehensive IP landscape report on Polymorph covering the USA, EU, and India, helping you stay informed, competitive, and compliant.
Built for both Innovator and Generic teams, Crystal Atlas empowers strategic decisions across R&D, regulatory, and IP functions — all in one place.
If you answered “yes” to any of the questions above or simply want to
explore further.
Explore our continuously growing database of polymorphic forms across globally
approved pharmaceutical products
Products from
2022
Products approved
in 2023
Products approved
in 2024
Products already
approved in 2025
Products in total
and counting...
Uddipak Consultancy Pvt. Ltd., founded in 2022 by Bharat Pagi, is a specialized pharmaceutical IP consultancy. Through our flagship solution, Crystal Atlas, we empower R&D, regulatory, and IP teams to make confident, data-driven decisions in polymorphism strategy. Our approach blends deep IP insight, scientific expertise, and up-to-date intelligence to support and strengthen your polymorphic form strategy.
Login now